Is Alkermes’ Schizophrenia Data Enough To Drive Demand?
Executive Summary
Alkermes showed that combo pill ALKS 3831 offers a better weight gain profile compared to olanzapine in schizophrenia patients, but analysts differed on whether the benefit would be great enough to drive demand against entrenched generics.
You may also be interested in...
Alkermes Expects Gradual Ramp-Up For Lybalvi Launch
Alkermes’ combo pill of olanzapine and samidorphan gets US FDA approval; company predicts $10m first-year sales as schizophrenia/bipolar patients cycle through treatment options, including generics.
12 Approvals To Look Out For In Q4
The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic areas. Here, Scrip takes a look at 12 of the more interesting approvals expected in the coming months, with the help of analysts at Biomedtracker.
Alkermes’ Pops Lays Out Novel Drug Vision For Year Ahead
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.